The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...
In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...
Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...
Some couples are restructuring their registries and celebrations to support charitable causes close to their hearts.
Will Hamilton, a Coromandel police officer who narrowly escaped death on the front line has been diagnosed with blood cancer and is now desperately trying ...
4h
A Coromandel police officer who narrowly escaped death on the frontline has been diagnosed with blood cancer and is now desperately trying to self-fund the life-saving drug he urgently needs. Will ...
Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback